<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04524273</url>
  </required_header>
  <id_info>
    <org_study_id>VIB0551.P3.S1</org_study_id>
    <nct_id>NCT04524273</nct_id>
  </id_info>
  <brief_title>Myasthenia Gravis Inebilizumab Trial</brief_title>
  <acronym>MINT</acronym>
  <official_title>A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study With Open-label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults With Myasthenia Gravis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viela Bio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viela Bio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, placebo-controlled, Phase 3, parallel-group study with optional&#xD;
      open-label extension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase 3, randomized, double-blind, placebo-controlled study, to be conducted&#xD;
      at approximately 100 study sites. Approximately 270 subjects (188 AChR-Ab+ and 82 MuSK-Ab+)&#xD;
      will be enrolled. Patients with MG who are positive for anti-AChR or anti-MuSK antibodies&#xD;
      will be enrolled and analyzed separately as 2 populations: (1) AChR-Ab+ and (2) MuSK-Ab+.&#xD;
      Patients who do not have anti-AChR or anti-MuSK antibodies will not be enrolled. Patients&#xD;
      with MGFA classification II, III, or IV disease, MG-ADL score ≥ 6, QMG score ≥ 11, and use of&#xD;
      a corticosteroid and/or non-steroidal immunosuppressant will be included in the study.&#xD;
&#xD;
      All subjects who complete the randomized controlled period will have the option to enroll in&#xD;
      a 1.5-year open-label period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2020</start_date>
  <completion_date type="Anticipated">December 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study with Open-label Period</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This is a double-blind study in which the IV inebilizumab and the IV placebo are matching in appearance.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) Profile score.</measure>
    <time_frame>Week 52 for AChR-Ab+ population and Week 26 for MuSK-Ab+ population</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quantitative Myasthenia Gravis (QMG) scores.</measure>
    <time_frame>Week 52 for AChR-Ab+ population and Week 26 for MuSK-Ab+ population</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with both (1) ≥ 3-point improvement in MG-ADL and (2) no use of rescue therapy.</measure>
    <time_frame>Week 52 for AChR-Ab+ population and Week 26 for MuSK-Ab+ population</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MG-ADL at Week 26 in the AChR-Ab+ population. (AChR-Ab+ Only)</measure>
    <time_frame>Week 26 for AChR-Ab+ population</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first exacerbation.</measure>
    <time_frame>Week 52 for AChR-Ab+ population and Week 26 for MuSK-Ab+ population</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Myasthenia Gravis Composite (MGC) score.</measure>
    <time_frame>Week 52 for AChR-Ab+ population and Week 26 for MuSK-Ab+ population</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Myasthenia Gravis Quality of Life-15, revised (MGQOL-15r) score.</measure>
    <time_frame>Week 52 for AChR-Ab+ population and Week 26 for MuSK-Ab+ population</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Global Impression of Change (PGIC) score.</measure>
    <time_frame>Week 52 for AChR-Ab+ population and Week 26 for MuSK-Ab+ population</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and treatment-emergent serious adverse events (TESAEs) during the randomized controlled period and open-label period.</measure>
    <time_frame>Week 52 for AChR-Ab+ population and Week 26 for MuSK-Ab+ population</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Myasthenia Gravis</condition>
  <arm_group>
    <arm_group_label>Inebilizumab, (AChR-Ab+) MG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive inebilizumab administered intravenously (IV) on Days 1, 15, and 183 of the randomized controlled period.&#xD;
During the open-label period, participants will receive inebilizumab administered IV on Days 1 and 183.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, (AChR-Ab+) MG</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo administered IV on Days 1 and 15 and on Day 183 of the randomized controlled period.&#xD;
During the open label period, participants will receive inebilizumab administered IV on Days 1, 15 and 183.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inebilizumab, (MuSK-Ab+) MG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive inebilizumab administered IV on Days 1 and 15 of the randomized controlled period.&#xD;
During the open-label period, participants will receive inebilizumab administered IV on Days 1 and 183</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, (MuSK-Ab+) MG</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo administered IV on Days 1 and 15 of the randomized controlled period.&#xD;
During the open label period, participants will receive inebilizumab administered IV on Days 1, 15 and 183</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inebilizumab</intervention_name>
    <description>Participants will receive IV inebilizumab</description>
    <arm_group_label>Inebilizumab, (AChR-Ab+) MG</arm_group_label>
    <arm_group_label>Inebilizumab, (MuSK-Ab+) MG</arm_group_label>
    <other_name>MEDI-551</other_name>
    <other_name>VIB0551</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Placebo</intervention_name>
    <description>Participants will receive IV placebo matched to inebilizumab</description>
    <arm_group_label>Placebo, (AChR-Ab+) MG</arm_group_label>
    <arm_group_label>Placebo, (MuSK-Ab+) MG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of MG with anti-AChR or anti-MuSK antibody.&#xD;
&#xD;
          2. MGFA Clinical Classification Class II, III, or IV.&#xD;
&#xD;
          3. MG-ADL score of 6 or greater at screening and at randomization with &gt; 50% of this&#xD;
             score attributed to non-ocular items.&#xD;
&#xD;
          4. QMG score of 11 or greater.&#xD;
&#xD;
          5. Subjects must be on:&#xD;
&#xD;
               1. Corticosteroids only, with no dose increase within 4 weeks prior to&#xD;
                  randomization, or&#xD;
&#xD;
               2. One allowed non-steroidal IST, with continuous use for at least 6 months prior to&#xD;
                  randomization and no dose increase within 4 months prior to randomization, or&#xD;
&#xD;
               3. Combination of (1) corticosteroids with no dose increase within 4 weeks prior to&#xD;
                  randomization and (2) one allowed non-steroidal IST with continuous use for at&#xD;
                  least 6 months prior to randomization and no dose increase within 4 months prior&#xD;
                  to randomization.&#xD;
&#xD;
        Allowed ISTs, alone or in combination with corticosteroids, are azathioprine, mycophenolate&#xD;
        mofetil, and mycophenolic acid.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Receipt within the 4 weeks prior to Day 1:&#xD;
&#xD;
               1. Cyclosporine (except eye drops)&#xD;
&#xD;
               2. Tacrolimus (except topical)&#xD;
&#xD;
               3. Methotrexate&#xD;
&#xD;
          2. Current use of:&#xD;
&#xD;
               1. Prednisone &gt; 40 mg/day or &gt; 80 mg over a 2-day period (or equivalent dose of&#xD;
                  other corticosteroids)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Horizon Therapeutics Study Director</last_name>
    <phone>1-866-479-6742</phone>
    <email>clinicaltrials@horizontherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 1010</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 1015</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 1013</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 1002</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 1005</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 1016</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 1012</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 1020</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 1018</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 1001</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 1009</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 1008</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 1019</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 1003</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 1014</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 1017</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 1004</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 1006</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 5203</name>
      <address>
        <city>Grodno</city>
        <zip>230030</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 5202</name>
      <address>
        <city>Minsk</city>
        <zip>220045</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 5204</name>
      <address>
        <city>Minsk</city>
        <zip>220114</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 5201</name>
      <address>
        <city>Vitebsk</city>
        <zip>210009</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 1104</name>
      <address>
        <city>West Vancouver</city>
        <zip>V7T1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 4006</name>
      <address>
        <city>Shanghai</city>
        <zip>201107</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 4004</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 5602</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 5601</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 3003</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 3001</name>
      <address>
        <city>Nice Cedex 01</city>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 3002</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 4104</name>
      <address>
        <city>Bangalore</city>
        <zip>560002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio investigative Site - 4105</name>
      <address>
        <city>Lucknow</city>
        <zip>226014</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 4103</name>
      <address>
        <city>Manipala</city>
        <zip>576104</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 4107</name>
      <address>
        <city>Nagpur</city>
        <zip>440009</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 4102</name>
      <address>
        <city>Nashik</city>
        <zip>422002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 4108</name>
      <address>
        <city>Pune</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 4109</name>
      <address>
        <city>Pune</city>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 4101</name>
      <address>
        <city>Surat</city>
        <zip>395002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 3204</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 3203</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 4401</name>
      <address>
        <city>Hanamaki</city>
        <zip>025-0082</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 4202</name>
      <address>
        <city>Seoul</city>
        <zip>3722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 4203</name>
      <address>
        <city>Seoul</city>
        <zip>5030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 4201</name>
      <address>
        <city>Seoul</city>
        <zip>6351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 5305</name>
      <address>
        <city>Samara</city>
        <zip>443095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 3403</name>
      <address>
        <city>Badalona</city>
        <zip>8916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 3402</name>
      <address>
        <city>Barcelona</city>
        <zip>8003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 3404</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 3401</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 4601</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio investigative Site - 4605</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 4606</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 4604</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 4603</name>
      <address>
        <city>Taipei</city>
        <zip>111</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 4602</name>
      <address>
        <city>Taoyuan City</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 5103</name>
      <address>
        <city>Dnipro</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 5105</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <zip>76493</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 5104</name>
      <address>
        <city>Lutsk</city>
        <zip>43005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 5101</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Viela Bio Investigative Site - 5106</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Canada</country>
    <country>China</country>
    <country>Denmark</country>
    <country>France</country>
    <country>India</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 10, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2020</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myasthenia Gravis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myasthenia Gravis</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

